Atezolizumab
- PDF / 168,819 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 26 Downloads / 171 Views
1 S
Immune-mediated hepatitis: case report In a multicenter, retrospective cohort study of 102 patients, who were treated at two different hospital in USA between 2010 and 2019, one patient [age and sex not stated] was described, who was re-challenged with atezolizumab after developing immunemediated hepatitis during treatment with atezolizumab for melanoma [route, dosage, duration of treatment to reaction onset and outcome not stated]. Li M, et al. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 126: 5088-5097, No. 23, 1 Dec 2020. 803520913 Available from: URL: http://doi.org/10.1002/cncr.33165
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
